

## Data Sharing Statement

<b>Article Info</b>	<a href="http://dx.doi.org/10.21037/tcr-20-3042">http://dx.doi.org/10.21037/tcr-20-3042</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The prevention and treatment value of intraportal oridonin for CRCLM in particular will be shared, and we also established a novel score figures of liver metastasis, which has seldom been provided in previous studies.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol, statistical analysis plan, informed consent form will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date.
7	To whom will you share the data?	Medical oncologists and colon cancer surgeons who are interested in studies of oridonin and CRCLM.
8	For what type of analysis or purpose?	For analysis to evaluate the prevention and treatment value of intraportal oridonin in CRCLM.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zoserbong@163.com
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.